Skip to main content
. 2022 Jan 1;12(1):434–458. doi: 10.7150/thno.67300

Figure 3.

Figure 3

Upconversion NPs for PDT-driven cancer immunotherapy. (A) Schematic illustration of UCN-Ce6-R837 nanoplatform-induced strong immune response, which combined with CTLA4 blockade to inhibit the relapse and metastasis of tumors. (B) DC maturation induced by various formulations. (C) Frequency of CD8+ CTLs\Treg cells in distant tumors treated with different formulations. (D) Growth curves of CT26 tumor-bearing mice after receiving different formulations. Reproduced with permission 68. Copyright 2017, American Chemical Society.